(Stroke. 2000;31:2212.)
© 2000 American Heart Association, Inc.
Original Contributions |
Intravenous Brain-Derived Neurotrophic Factor Reduces Infarct Size and Counterregulates Bax and Bcl-2 Expression After Temporary Focal Cerebral Ischemia
From the Departments of Neurology (W-R.S., W.Z., M.S., S.S.) and Neuropathology (C.S., M.K.), University of Heidelberg (Germany).
Correspondence to Wolf-R. Schäbitz, MD, Department of Neurology, University of Heidelberg, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany. E-mail wolf_schaebitz{at}med.uni-heidelberg.de
Background and Purpose—Pretreatment with intraventricular brain-derived neurotrophic factor (BDNF) reduces ischemic damage after focal cerebral ischemia. In this experiment we studied the effect of intravenous BDNF delivered after focal cerebral ischemia on neurological outcome, infarct size, and expression of proapoptotic and antiapoptotic proteins Bax and Bcl-2, respectively.
Methods—With the use of the suture occlusion technique, the right middle cerebral artery in rats was temporarily occluded for 2 hours. Thirty minutes after vessel occlusion, BDNF (300 µg/kg per hour in vehicle; n=12) or vehicle alone (n=13) was continuously infused intravenously for 3 hours. After 24 hours the animals were weighed and neurologically assessed on a 5-point scale. The animals were then killed, and brains underwent either 2,3,5-triphenyltetrazolium chloride staining for assessment of infarct volume or paraffin embedding for morphology and immunohistochemistry (Bax, Bcl-2).
Results—Physiological parameters (mean arterial blood pressure, PO2, PCO2, pH, body temperature, glucose) and weight revealed no difference between groups. Neurological deficit was improved in BDNF-treated animals versus controls (P<0.05, unpaired, 2-tailed t test). Mean±SD infarct volume was 229.7±97.7 mm3 in controls and 121.3±80.2 mm3 in BDNF-treated animals (P<0.05, unpaired, 2-tailed t test). Cortical infarct volume was 155.5±78.5 mm3 in the placebo group and 69.9±50.2 mm3 in the BDNF-treated group (P<0.05, unpaired, 2-tailed t test). Subcortical infarct volume was 74.1±30.6 mm3 in the placebo group and 51.1±26.8 mm3 in the BDNF-treated group (P=NS). Bax-positive neurons were significantly reduced in the ischemic penumbra in BDNF-treated animals (P<0.05, unpaired, 2-tailed t test), whereas Bcl-2–positive neurons were significantly increased in this area (P<0.001, unpaired, 2-tailed t test).
Conclusions—This study demonstrates a neuroprotective effect of BDNF when delivered intravenously after onset of focal cerebral ischemia. As shown here, one possible mechanism of action of neuroprotection of BDNF after focal ischemia appears to be counterregulation of Bax/Bcl-2 proteins within the ischemic penumbra.
Editorial Comment
Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts
This article has been cited by other articles:
 |
|
 |
|
  W.-R. Schabitz, T. Steigleder, C. M. Cooper-Kuhn, S. Schwab, C. Sommer, A. Schneider, and H. G. Kuhn Intravenous Brain-Derived Neurotrophic Factor Enhances Poststroke Sensorimotor Recovery and Stimulates Neurogenesis Stroke, July 1, 2007; 38(7): 2165 - 2172. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. J. Lee, K. S. Kim, E. J. Kim, H. B. Choi, K. H. Lee, I. H. Park, Y. Ko, S. W. Jeong, and S. U. Kim Brain Transplantation of Immortalized Human Neural Stem Cells Promotes Functional Recovery in Mouse Intracerebral Hemorrhage Stroke Model Stem Cells, May 1, 2007; 25(5): 1204 - 1212. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. D. Qian, J. Zhang, X.-Y. Tan, A. Wood, D. Gill, and S. Cho Novel Agonist Monoclonal Antibodies Activate TrkB Receptors and Demonstrate Potent Neurotrophic Activities. J. Neurosci., September 13, 2006; 26(37): 9394 - 9403. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Solaroglu, J. Cahill, V. Jadhav, and J. H. Zhang A Novel Neuroprotectant Granulocyte-Colony Stimulating Factor Stroke, April 1, 2006; 37(4): 1123 - 1128. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Fisher, A. Davalos, A. Rogalewski, A. Schneider, E. B. Ringelstein, and W.-R. Schabitz Toward a Multimodal Neuroprotective Treatment of Stroke Stroke, April 1, 2006; 37(4): 1129 - 1136. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Vaynman and F. Gomez-Pinilla License to Run: Exercise Impacts Functional Plasticity in the Intact and Injured Central Nervous System by Using Neurotrophins Neurorehabil Neural Repair, December 1, 2005; 19(4): 283 - 295. [Abstract] [PDF]
|
|
|
|
 |
|
 I. Husson, C.-M. Rangon, V. Lelievre, A.-P. Bemelmans, P. Sachs, J. Mallet, B. E. Kosofsky, and P. Gressens BDNF-induced White Matter Neuroprotection and Stage-dependent Neuronal Survival Following a Neonatal Excitotoxic Challenge Cereb Cortex, March 1, 2005; 15(3): 250 - 261. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Kim, Q. Li, B. L. Hempstead, and J. A. Madri Paracrine and Autocrine Functions of Brain-derived Neurotrophic Factor (BDNF) and Nerve Growth Factor (NGF) in Brain-derived Endothelial Cells J. Biol. Chem., August 6, 2004; 279(32): 33538 - 33546. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W.-R. Schabitz, C. Berger, R. Kollmar, M. Seitz, E. Tanay, M. Kiessling, S. Schwab, and C. Sommer Effect of Brain-Derived Neurotrophic Factor Treatment and Forced Arm Use on Functional Motor Recovery After Small Cortical Ischemia Stroke, April 1, 2004; 35(4): 992 - 997. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Lou, C. C. Eschenfelder, T. Herdegen, S. Brecht, and G. Deuschl Therapeutic Window for Use of Hyperbaric Oxygenation in Focal Transient Ischemia in Rats Stroke, February 1, 2004; 35(2): 578 - 583. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Shimamura, N. Sato, K. Oshima, M. Aoki, H. Kurinami, S. Waguri, Y. Uchiyama, T. Ogihara, Y. Kaneda, and R. Morishita Novel Therapeutic Strategy to Treat Brain Ischemia: Overexpression of Hepatocyte Growth Factor Gene Reduced Ischemic Injury Without Cerebral Edema in Rat Model Circulation, January 27, 2004; 109(3): 424 - 431. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Duan, Z. Guo, H. Jiang, M. Ware, X.-J. Li, and M. P. Mattson Dietary restriction normalizes glucose metabolism and BDNF levels, slows disease progression, and increases survival in huntingtin mutant mice PNAS, March 4, 2003; 100(5): 2911 - 2916. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W.-R. Schabitz, R. Kollmar, M. Schwaninger, E. Juettler, J. Bardutzky, M.N. Scholzke, C. Sommer, and S. Schwab Neuroprotective Effect of Granulocyte Colony-Stimulating Factor After Focal Cerebral Ischemia Stroke, March 1, 2003; 34(3): 745 - 751. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. C. DeVries, H.-D. Joh, O. Bernard, K. Hattori, P. D. Hurn, R. J. Traystman, and N. J. Alkayed Social stress exacerbates stroke outcome by suppressing Bcl-2 expression PNAS, September 5, 2001; (2001) 201215298. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Zhang, W. M. Pardridge, and R. F. Keep Neuroprotection in Transient Focal Brain Ischemia After Delayed Intravenous Administration of Brain-Derived Neurotrophic Factor Conjugated to a Blood-Brain Barrier Drug Targeting System Editorial Comment Stroke, June 1, 2001; 32(6): 1378 - 1384. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W.-R. Schabitz, T. T. Hoffmann, S. Heiland, R. Kollmar, J. Bardutzky, C. Sommer, and S. Schwab Delayed Neuroprotective Effect of Insulin-Like Growth Factor-I After Experimental Transient Focal Cerebral Ischemia Monitored With MRI Stroke, May 1, 2001; 32(5): 1226 - 1233. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Fisher and W. Schaebitz An Overview of Acute Stroke Therapy: Past, Present, and Future Arch Intern Med, November 27, 2000; 160(21): 3196 - 3206. [Full Text] [PDF]
|
|
|
|
|
|
A. C. DeVries, H.-D. Joh, O. Bernard, K. Hattori, P. D. Hurn, R. J. Traystman, and N. J. Alkayed Social stress exacerbates stroke outcome by suppressing Bcl-2 expression PNAS, September 25, 2001; 98(20): 11824 - 11828. [Abstract] [Full Text] [PDF]
|
|